Efficacy and Safety of Sintilimab Combined with FOLFOX Regimen in the Treatment of Advanced Unresectable Primary Liver Cancer
Objective To analyze the efficacy and safety of sintilimab combined with FOLFOX regimen(oxaliplatin+calcium folinate+fluorouracil)in the treatment of advanced unresectable primary liver cancer.Methods The clinical data of 83 patients with advanced unresectable primary liver cancer were retrospectively analyzed.48 patients treated with FOLFOX regimen were included in the control group,and 35 patients treated with sintilimab combined with FOLFOX regimen were included in the combination group.The clinical efficacy,levels of tumor markers[alpha fetoprotein(AFP),Carcinoembryonic antigen(CEA),car-bohydrate antigen-199(CA-199)],T lymphocyte subsets(CD3+,CD4+,CD8+,CD4+/CD8+)and adverse drug reactions were compared between the 2 groups.Results After treatment,the disease control rate(DCR)of the combination group patients was higher than that of the control group(P＜0.05).After treatment,the levels of AFP,CEA,and CA-199 in both groups of patients decreased compared to before treatment,and the combination group was lower than the control group(P＜0.05).After treatment,the CD3+,CD4+,CD4+/CD8+levels in the combination group increased compared to before treatment,while CD8+levels de-creased compared to before treatment.The CD3+,CD4+,CD4+/CD8+levels in the control group decreased compared to before treatment,while CD8+levels increased compared to before treatment(P＜0.05).During the treatment process,there was no sta-tistical significant difference in the incidence of gastrointestinal reactions,hematological reactions,neurological reactions,allergic sensitization,and thyroid dysfunction between the 2 groups of patients(P＞0.05).Conclusion Sintilimab combined with FOL-FOX regimen has good clinical efficacy in the treatment of advanced unresectable primary liver cancer,which can effectively im-prove the level of tumor markers and immune function of patients,and has good safety.
NETL
NSTL
万方数据
